Michael Drucker
Novant Health
Control of respirationInternal medicineLead (electronics)CardiologyClinical endpointStimulationCardiac resynchronization therapyImplantable cardioverter-defibrillatorPhrenic nerveVeinHeart failureAtrial fibrillationCentral sleep apneaImplantBreathingAnesthesiaConfidence intervalMedicineCohort
2Publications
2H-index
11Citations
Publications 3
Newest
#1Michael Drucker (Novant Health)H-Index: 2
#2Harish Manyam (Erlanger Health System)
Last. Kimberly A. Parks (Harvard University)H-Index: 12
view all 8 authors...
BACKGROUND Multisite LV stimulation therapy allows for stimulation of two different left ventricular pacing vectors within a single LV lead and may improve responsiveness to cardiac resynchronization therapy (CRT). This study prospectively evaluated the safety and efficacy of the MultiPole Pacing (MPP) feature in CRT non-responder patients. METHODS AND RESULTS CRT non-responders with a standard CRT-D indication were eligible for enrollment into the MPP Sub-Study. Patient status, NYHA classificat...
Source
#1Naushad A. ShaikH-Index: 1
#2Michael Drucker (Novant Health)H-Index: 2
Last. George Thomas (Cornell University)H-Index: 17
view all 8 authors...
INTRODUCTION: The novel two-lead CRT-DX system utilizes a floating atrial dipole on the implantable cardioverter-defibrillator (ICD) lead, and when implanted with an LV lead, offers a two-lead cardiac resynchronization therapy (CRT) system with AV synchrony. This study compared complication rates and CRT response among subjects implanted with a two-lead CRT-DX system to those subjects implanted with a standard three-lead CRT-D system. METHODS AND RESULTS: A total of 240 subjects from the QP ExCE...
3 CitationsSource
#1Ralph Augostini (The Ohio State University Wexner Medical Center)H-Index: 17
#2Muhammad R. Afzal (The Ohio State University Wexner Medical Center)H-Index: 14
Last. Dariusz JagielskiH-Index: 7
view all 16 authors...
BACKGROUND: Central sleep apnea (CSA) is a breathing disorder caused by the intermittent absence of central respiratory drive. Transvenous phrenic nerve stimulation is a new therapeutic option, recently approved by the FDA , for the treatment of CSA. OBJECTIVE: To describe the technique used to implant the transvenous phrenic nerve stimulation system (the remedē System, Respicardia, Inc). METHODS: The remedē System is placed in the pectoral region, typically on the right side. A single stimulati...
9 CitationsSource